Novo Nordisk's Buyback Blitz Masks Building Pressure Ahead of 2027 Price Cuts
Published on 07/14/2026 at 14:06 | Redaktion boerse-global.de
The Danish pharmaceutical heavyweight is buying back shares at a record pace, yet the same weekly disclosures that reveal rising purchase prices also show a company facing a fundamental test. Novo Nordisk has spent roughly 6.53 billion Danish kroner since early February to repurchase nearly 24 million B-shares, a move that has helped drive a 13% one-month recovery in the stock. But beneath that buyback-driven optimism, the market is wrestling with a question that will determine the next leg of the story: can oral semaglutide scale fast enough to offset a planned 50% U.S. price cut on Wegovy starting in January 2027?
The current tranche of the 15-billion-kroner buyback program began on 6 May 2026 and runs alongside a broader 12-month mandate that extends until 1 February 2027. As of 10 July, Novo Nordisk had repurchased 23,984,179 B-shares at an average price of 272.45 kroner, pushing the total held as treasury shares to 41,169,480 — equivalent to 0.9% of share capital. The pace is accelerating: one week earlier, the average purchase price stood at 270.32 kroner, signalling that management is willing to pay up even as the stock recovers from its March trough.
Yet the buyback narrative coexists with mounting headwinds. Deutsche Bank, citing IQVIA prescription data, has warned of a slowdown in oral Wegovy prescriptions. The injectable version of semaglutide already faces a structural threat: under current U.S. pricing rules, Wegovy could see cuts of around 50% from January 2027, with Ozempic facing roughly 35% reductions. That timeline aligns uncomfortably with the first cracks in the semaglutide patent fortress — Health Canada has already approved a generic called SEVMIA, and analysts at SB1 Markets expect meaningful revenue erosion from generics by the second half of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The bull case rests entirely on the oral Wegovy tablet, which has surpassed 3 million prescriptions and offers a simpler patient experience than injections. CVS Health has expanded its GLP-1 coverage for Medicare patients, potentially capping co-pays at $50 per month, and Novo Nordisk's recent launch of the weekly basal insulin Awiqli in India demonstrates continued international expansion. If oral Wegovy maintains its momentum, some analysts project revenues 60% above current consensus by 2028 — a scenario that could cushion the price shocks.
On the charts, the stock closed Monday at €43.20, up nearly 14% in a month but still 27% below its level a year ago. It sits above both the 50-day moving average of €39.62 and the 200-day moving average of €40.57, with a relative strength index of 65 — suggesting room to run without entering overbought territory. Yet the 29% annualised volatility underscores the uncertainty. The 52-week high of €60.95 from July 2025 remains nearly 30% out of reach, and the €42.86 current price (down 0.80% on the day) still leaves the stock below its 200-day average in euro terms.
The tension between these forces will come to a head on 5 August 2026, when Novo Nordisk reports second-quarter results. If oral Wegovy sales convincingly beat consensus, the stock could extend its rally above the 50-day line. But if the Deutsche Bank warning proves prescient and prescription data weakens further, or if Canadian generic competition accelerates margin erosion, the shares may retest support near €39.71. For now, management is voting with capital — nearly a million B-shares bought each week — but the market is holding its breath for the numbers that will decide whether that confidence is justified.
Ad
Novo Nordisk Stock: New Analysis - 14 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
